✦ LIBER ✦

Cost-effectiveness analysis of irinotecan+5FU/FA versus oxaliplatin+5FU/FA first-line therapy in advanced colorectal cancer in the UK

✍ Scribed by A. Bearne; A. Burrell

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III trial of bolus 5-fluorouracil

✍ A. Grothey; T. Buechele; H. Kroening; K. Ridwelski; P. Reichardt; A. Kretzschmar 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 163 KB

664 PUBLICATION Cetuximab in combination

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 137 KB

CH1: COST-EFFECTIVENESS ANALYSIS OF IRIN

✍ C Schmitt; C Levy-Piedbois; M Frappe; I Durand-Zaleski 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

Factors predicting for efficacy of oxali

✍ M.A Bensmaı̈ne; A de Gramont; S Brienza; M Marty; F Lévi; M Ducreux; E François; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 155 KB

3004 ORAL Cetuximab plus 5-FU/FA/oxalipl

✍ C. Bokemeyer; E. Staroslawska; A. Makhson; I. Bondarenko; J.T. Hartmann; Y. Shel 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

631 POSTER Cost-effectiveness analysis o

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 144 KB